Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Aardvark Therapeutics, Inc.. The associated price target remains the same with $29.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Ulz has given his Buy rating due to a combination of factors highlighting the promising potential of Aardvark Therapeutics, Inc.’s pipeline. The preclinical data for ARD-201, a combination of ARD-101 and a DPP4 inhibitor, demonstrated significant reductions in fat mass while preserving muscle mass, which is comparable to existing treatments like tirzepatide. Furthermore, ARD-201 showed notable improvements in glucose tolerance, suggesting a differentiated profile in obesity treatment.
Additionally, the Phase 2a data for ARD-101 indicated weight loss and reduced hunger in obese patients, supporting its potential efficacy. Although ARD-101 is primarily being developed for hyperphagia associated with Prader-Willi syndrome, these findings could enhance the prospects of ARD-201. The company is also advancing its pipeline with the upcoming Phase 2 studies for ARD-201 and the ongoing Phase 3 study for ARD-101, which are expected to yield further insights into their therapeutic potential.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AARD in relation to earlier this year.